Amgen Beats Q2 Earnings Estimates, Raises Full-Year Guidance

Amgen announced its financial results for the second quarter of 2026. The company's profit exceeded market expectations, and management revised its full-year outlook upward. These positive developments are seen as an indication of the company's strong operational performance. Additionally, Amgen reported that it has terminated the development program for its drug candidate AMG 513. This decision appears to be part of the company's strategy to prioritize its R&D portfolio. The discontinuation of AMG 513 may point to a reduction in research expenses in the near term. The company's second-quarter revenues surpassed expectations, driven by strong product sales and operational efficiency. In particular, the performance of the existing drug portfolio contributed significantly to growth. Management anticipates that this momentum will continue through the rest of the year. Amgen raised both its revenue and earnings forecasts for the full year. This revision reflects the company's confidence in adapting to market conditions and sustaining its growth potential. Investors may react positively to these signals in the stock price. This is not investment advice.